Standard BioTools Inc. LAB

Company Overview

Standard BioTools Inc. (NASDAQ: LAB) is a life sciences tools and biotechnology instrumentation company focused on enabling high-parameter biological analysis for academic, translational, and biopharmaceutical research customers. The company operates primarily in the proteomics and genomics markets, providing instruments, consumables, software, and services used in biomarker discovery, immune profiling, single-cell analysis, and spatial biology research. The company was formed through the rebranding of Fluidigm Corporation following the acquisition of Standard BioTools Holdings Limited, the parent company of SomaLogic, and now positions itself as a multi-omics platform provider serving researchers engaged in precision medicine and systems biology applications.

The company’s principal revenue drivers include sales of analytical instruments, recurring consumables, assay kits, and laboratory services tied to its proteomics and genomics platforms. Standard BioTools serves pharmaceutical and biotechnology companies, academic research institutions, clinical research organizations, and government laboratories. Its strategic positioning centers on integrating high-throughput proteomic and genomic analysis with scalable workflows designed for translational research and drug development. Originally founded as Fluidigm in 1999, the company initially focused on microfluidics-based genomic technologies before expanding into mass cytometry and proteomics through acquisitions and internal development initiatives.